Peptide Lab HQ Research Guide
Adamax
A research-focused compound profile covering Adamax identity, Semax-analog research, ACTH-fragment pathway context, neurotrophic signaling models, concentration reference, preparation reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Adamax |
|---|---|
| Common Research Name | Adamantane-modified Semax analog |
| Common Synonyms | Adamax peptide, Ac-Semax-Adamantyl, Adamantane Semax, Ac-MEHFPGP-AG-NH₂ |
| Compound Type | Synthetic modified neuropeptide / Semax analog / ACTH-fragment analog research peptide |
| CAS Number | Not consistently assigned across public references; verify against supplier COA |
| Amino Acid Length | Semax-derived heptapeptide core with terminal modification; public references vary by notation |
| Core Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Common Modified Sequence Notation | Ac-MEHFPGP-AG-NH₂; verify exact adamantane notation against supplier COA |
| Structural Modification | N-terminal acetylation plus adamantane-containing C-terminal modification intended for altered stability and lipophilicity in research models |
| Molecular Formula | Form/source-dependent; public references vary significantly, so verify against supplier COA |
| Molecular Weight | Form/source-dependent; commonly referenced around 1,000 Da, but verify against supplier COA |
| Research Category | Semax analog, ACTH-fragment analog, neurotrophic signaling, BDNF pathway context, neuroplasticity, cognitive-function, and CNS peptide research |
| Research Context | Commonly discussed in preclinical neurotrophic signaling, peptide-stability, CNS exposure, and Semax-comparison research models. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Adamax is commonly discussed in controlled research models involving Semax-analog activity, ACTH-fragment pathway context, neurotrophic signaling, BDNF-related observations, TrkB pathway context, synaptic plasticity, peptide stability, and CNS exposure modeling.
Semax-Analog Research
Adamax is commonly positioned as a modified Semax analog with terminal modifications used to study altered peptide behavior relative to the parent Semax structure.
ACTH-Fragment Context
Because Adamax is derived from the Semax core sequence, it is commonly discussed in ACTH-fragment analog and neuropeptide signaling research.
Neurotrophic Signaling Models
Adamax is often discussed in research contexts involving BDNF expression, TrkB pathway sensitivity, neuronal survival signaling, and neurotrophic pathway observations.
Neuroplasticity Research
Used in research discussions involving synaptic plasticity, learning-related pathway models, memory-related observations, and CNS adaptation markers.
Peptide Stability Research
The acetyl and adamantane-related modifications are commonly discussed as structural tools for investigating enzymatic stability, lipophilicity, and peptide-resistance behavior.
CNS Exposure Models
Adamax is commonly discussed in relation to improved lipophilicity and CNS exposure modeling compared with less-modified Semax-family peptides.
Research Scope
These applications are provided for educational and research-reference purposes only. Adamax research is limited compared with Semax and other better-characterized peptide categories, and outcomes may vary based on structural form, purity, model type, concentration, route, exposure duration, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 20 mg Adamax |
|---|---|
| Primary Solution Volume | 1.0 mL bacteriostatic water |
| Primary Concentration | 20 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 20 mg/mL, 1 unit equals 0.2 mg / 200 mcg Adamax. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Because this is a concentrated 20 mg/mL preparation, verify complete dissolution before recording final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Adamax, commonly described as a synthetic Semax-derived peptide analogue | Adamax is commonly discussed as a modified Semax-style peptide with N-terminal and C-terminal modifications intended for neuropeptide and cognitive-marker research contexts. |
| Sequence / Structure Reference | Commonly referenced as Ac-MEHFPGP-AG-NH2 or similar Adamax notation | Supplier and database references may vary in notation. Verify the exact sequence, salt form, purity, and identity against the COA, batch record, or formula record when available. |
| Semax-Analogue Research Context | Model-dependent concentration and endpoint tracking | Commonly discussed in relation to Semax-analogue, ACTH-fragment analogue, neuropeptide, cognitive-function, neuroplasticity, and central nervous system marker research. |
| Neurotrophic-Marker Research | BDNF / TrkB pathway discussion context | Adamax-related research discussions commonly reference BDNF expression, TrkB receptor sensitivity, synaptic plasticity, hippocampal signaling, and neurotrophic-marker observations. |
| Neuroprotection / Stress-Response Research | Experimental and model-dependent context | Commonly discussed in neuroprotection, neuronal survival, oxidative-stress marker, inflammation-related marker, cognitive-stress model, and recovery-marker research contexts. |
| Stability / Lipophilicity Research Context | Adamantane-related modification context | Public references commonly discuss Adamax as a modified peptide with an adamantane-associated terminal feature, often framed around stability, lipophilicity, and peptide-degradation research discussion. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references may describe Adamax in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, anecdotal reports, or wellness protocols should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 20 mg | 1.0 mL | 20 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 20 mg/mL | U-100 Unit Reference | Approx. References per 20 mg Vial |
|---|---|---|---|
| 50 mcg | 0.0025 mL | 0.25 units | 400 |
| 100 mcg | 0.005 mL | 0.5 units | 200 |
| 0.25 mg / 250 mcg | 0.0125 mL | 1.25 units | 80 |
| 0.5 mg / 500 mcg | 0.025 mL | 2.5 units | 40 |
| 1 mg / 1000 mcg | 0.05 mL | 5 units | 20 |
| 2 mg / 2000 mcg | 0.10 mL | 10 units | 10 |
| 5 mg / 5000 mcg | 0.25 mL | 25 units | 4 |
| 10 mg / 10000 mcg | 0.50 mL | 50 units | 2 |
| 20 mg / 20000 mcg | 1.00 mL | 100 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Microgram Reference | Calculation reference only | 50 mcg reference amount | 0.25 units / 0.0025 mL |
| Standard Microgram Reference | Calculation reference only | 100 mcg reference amount | 0.5 units / 0.005 mL |
| Low Milligram Conversion Example | Public protocol-style reference, not a clinical dosing standard | 250 mcg reference amount | 1.25 units / 0.0125 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 2.5 units / 0.025 mL |
| Upper Conversion Example | Calculation reference only | 1 mg reference amount | 5 units / 0.05 mL |
| High Conversion Example | Calculation reference only | 2 mg reference amount | 10 units / 0.10 mL |
| Quarter-Vial Preparation Reference | Preparation-level calculation reference | 5 mg reference amount | 25 units / 0.25 mL |
| Half-Vial Preparation Reference | Preparation-level calculation reference | 10 mg reference amount | 50 units / 0.50 mL |
| Full-Vial Preparation Reference | Preparation-level calculation reference | 20 mg reference amount | 100 units / 1.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Neurotrophic Marker Window | 24–72 hours | May be used for BDNF / TrkB marker observation, neurotrophic-response markers, synaptic-plasticity markers, neuronal-survival markers, or peptide-response documentation depending on the model. |
| Acute Neurocognitive Observation Window | Single session to several days | Used for short-term cognitive-marker comparison, stress-response marker observation, neuroprotective-marker tracking, or early pathway documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for short-duration controlled observation involving cognitive-function markers, neuroplasticity markers, stress-response, or neuronal-response endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for neurotrophic-marker trends, cognitive-marker tracking, neuroprotective context, or follow-up marker documentation. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Adamax is commonly discussed in Semax-analogue, ACTH-fragment analogue, neuropeptide, BDNF / TrkB, cognitive-marker, neuroplasticity, synaptic-response, neuronal-survival, neuroprotection, and stress-response research contexts. This reference uses a 20 mg vial reconstituted with 1.0 mL bacteriostatic water, creating a 20 mg/mL concentration. Higher-concentration preparations may require supplier-specific handling, solvent-volume, or solubility notes; verify against the COA, batch record, or formula record when available. Published study references, public protocol-style references, anecdotal reports, and wellness protocols are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Adamax is commonly discussed in research involving Semax-analog activity, ACTH-fragment pathway context, neurotrophic signaling, BDNF-related observations, TrkB pathway context, synaptic plasticity, peptide stability, and CNS exposure modeling.
Study Limitations
Adamax research is limited compared with Semax and other better-characterized peptide categories. Findings should be interpreted according to structural form, modified sequence notation, peptide purity, model type, concentration, exposure duration, and endpoint selection.
Safety Considerations
Research discussion should account for peptide identity verification, modified sequence confirmation, adamantane-related form verification, sterility documentation, endotoxin risk, supplier qualification, batch records, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.